Results 221 to 230 of about 54,453 (265)

Human medicines European public assessment report (EPAR): Zessly, infliximab, Arthritis, Psoriatic,Psoriasis,Crohn Disease,Arthritis, Rheumatoid,Colitis, Ulcerative,Spondylitis, Ankylosing, Date of authorisation: 18/05/2018, Revision: 3, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

Pathogenesis of ankylosing spondylitis — recent advances and future directions

Nature Reviews Rheumatology, 2017
Robert Inman, Matthew A Brown, Eric Gracey   +2 more
exaly  

Human medicines European public assessment report (EPAR): Zessly, infliximab, Arthritis, Psoriatic,Psoriasis,Crohn Disease,Arthritis, Rheumatoid,Colitis, Ulcerative,Spondylitis, Ankylosing, Date of authorisation: 18/05/2018, Revision: 2, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Lancet, The, 2002
Juergen Braun, W Golder, H Sorensen
exaly  

Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 16, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

TNFAIP3-DEPTOR complex regulates inflammasome secretion through autophagy in ankylosing spondylitis monocytes

Autophagy, 2018
Fenyong Liu, Huanyu Lu, Ping Zhu
exaly  

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Spondylitis, Ankylosing,Arthritis, Rheumatoid,Crohn Disease,Colitis, Ulcerative,Arthritis, Psoriatic,Psoriasis, Date of authorisation: 26/05/2016, Revision: 8, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

<p>Advances in nanomedicine for the treatment of ankylosing spondylitis</p>

International Journal of Nanomedicine, 2019
Birendra Chaurasiya, Thomas Webster, Thomas Webster   +2 more
exaly  

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Spondylitis, Ankylosing,Arthritis, Rheumatoid,Crohn Disease,Colitis, Ulcerative,Arthritis, Psoriatic,Psoriasis, Date of authorisation: 26/05/2016, Revision: 10, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

Human medicines European public assessment report (EPAR): Solymbic, adalimumab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Crohn Disease,Colitis, Ulcerative,Hidradenitis Suppurativa,Psoriasis,Arthritis, Rheumatoid, Date of authorisation: 22/03/2017, Revision: 2, Status: Withdrawn

Case Medical Research, 2019
openaire   +2 more sources